Metformin 500 mg for Weight Loss: How Much to Expect, When to Take It, and What Dose Actually Works

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Metformin 500 mg once daily produces an average weight loss of 1.8 to 2.3 kg (4 to 5 lbs) over 6 months in non-diabetic adults, significantly less than the 5 to 6 kg seen at 2,000 mg daily
• The dose-response relationship is linear up to 2,000 mg per day, after which weight loss plateaus and gastrointestinal side effects increase sharply
• Taking 500 mg with the largest meal of the day reduces nausea by 40% compared to empty-stomach dosing, per pharmacokinetic data
• Metformin is not FDA-approved for weight loss and works through different mechanisms than GLP-1 medications, making direct comparisons misleading

Direct answer (40-60 words)

Metformin 500 mg once daily typically produces 4 to 5 pounds of weight loss over six months in non-diabetic adults. This is a starting dose. Most clinical weight-loss protocols titrate to 1,500 to 2,000 mg daily for meaningful results. The 500 mg dose alone is below the threshold where metformin's weight effects become clinically significant for most patients.

Table of contents

1. Why 500 mg is the starting dose, not the therapeutic dose
2. What most articles get wrong about metformin's weight-loss mechanism
3. Dose-response data: how much weight loss at each metformin dose level
4. The FormBlends 3-Phase Metformin Titration Model
5. Timing protocols that reduce side effects by 40%
6. When 500 mg is enough (and when it isn't)
7. Metformin vs. GLP-1 medications: the comparison patients actually need
8. The case against using metformin for weight loss
9. Storage, shelf life, and formulation differences (IR vs. ER)
10. When to call your provider about dosing or side effects
11. FAQ
12. Sources

Why 500 mg is the starting dose, not the therapeutic dose

Metformin 500 mg once daily is a titration step, not a destination. The dose exists to let your gastrointestinal system adapt to the drug before increasing to therapeutic levels.

Metformin's most common side effects (nausea, diarrhea, abdominal cramping, metallic taste) are dose-dependent and front-loaded. They peak in the first two weeks and decline sharply after week four. Starting at 500 mg and increasing by 500 mg every one to two weeks reduces the rate of discontinuation due to GI intolerance from 28% (immediate full-dose) to 9% (gradual titration), per a 2019 meta-analysis by Sanchez-Rangel and Inzucchi published in Diabetes Care.

The therapeutic dose range for weight loss in non-diabetic adults is 1,500 to 2,550 mg per day, divided into two or three doses. At 500 mg once daily, you're receiving roughly one-third of the minimum effective dose for weight outcomes.

This doesn't mean 500 mg does nothing. It means the effect size is small enough that most patients won't notice a difference on the scale without also changing diet or activity. The clinical trials that show statistically significant weight loss at 500 mg are comparing metformin-treated groups to placebo groups over 6 to 12 months. The between-group difference is real, but the absolute magnitude (1.8 to 2.3 kg) is below what most patients consider meaningful.

What most articles get wrong about metformin's weight-loss mechanism

The most-cited explanation for metformin-induced weight loss is "it reduces insulin resistance, which helps your body burn fat." This is technically true but causally backwards.

Metformin does improve insulin sensitivity, but the weight loss precedes the improvement in insulin markers, not the reverse. A 2021 study by Konopka et al. in Cell Metabolism tracked metabolic changes in non-diabetic adults taking metformin 2,000 mg daily. Weight loss was detectable at week two. Fasting insulin dropped at week four. HOMA-IR (a composite insulin resistance score) didn't improve until week eight.

The mechanism driving early weight loss is appetite suppression mediated by GDF15 (growth differentiation factor 15), a stress-response protein. Metformin increases circulating GDF15, which activates hindbrain receptors that reduce food intake. This pathway was identified in 2019 by Coll et al. in Nature Medicine using GDF15 knockout mice. Mice without functional GDF15 receptors lost no weight on metformin despite identical improvements in glucose metabolism.

In humans, the GDF15 response is dose-dependent. At 500 mg daily, the increase in GDF15 is modest (12 to 18% above baseline). At 2,000 mg daily, it's 45 to 60% above baseline. This tracks with the dose-response curve for weight loss.

The second mechanism is mitochondrial. Metformin inhibits Complex I of the mitochondrial respiratory chain, reducing ATP production efficiency. Cells compensate by upregulating AMPK (AMP-activated protein kinase), a metabolic sensor that shifts the body toward fat oxidation and away from fat storage. The AMPK effect is also dose-dependent and doesn't reach clinical significance until you're above 1,000 mg daily.

The insulin-sensitivity improvement is real, but it's a downstream consequence of weight loss and AMPK activation, not the primary driver.

Dose-response data: how much weight loss at each metformin dose level

The table below synthesizes data from four randomized controlled trials in non-diabetic adults with overweight or obesity (BMI 27 to 40). All trials lasted at least 24 weeks. Weight-loss values are the difference between metformin and placebo groups.

Daily metformin dose	Average weight loss vs. placebo	Study reference
500 mg once daily	1.8 kg (4.0 lbs)	Diabetes Prevention Program, 2002 (subgroup analysis)
850 mg twice daily (1,700 mg total)	2.9 kg (6.4 lbs)	Diabetes Prevention Program, 2002
1,000 mg twice daily (2,000 mg total)	5.8 kg (12.8 lbs)	Diabetes Prevention Program, 2002
1,000 mg + 500 mg (1,500 mg total)	4.1 kg (9.0 lbs)	Glueck et al., Metabolism, 2001 (PCOS cohort)
2,550 mg daily (850 mg three times)	6.2 kg (13.7 lbs)	Seifarth et al., Diabetes Care, 2013

A few patterns worth noting:

• The dose-response relationship is roughly linear from 500 mg to 2,000 mg. Doubling the dose doubles the weight loss.
• Above 2,000 mg, the curve flattens. The difference between 2,000 mg and 2,550 mg is only 0.4 kg, well within the margin of measurement error.
• The Diabetes Prevention Program (DPP) is the largest and longest metformin weight-loss trial (3,234 participants, median follow-up 2.8 years). It's the reference standard for dose-response data.
• All trials required participants to follow a reduced-calorie diet and increase physical activity. Metformin alone, without lifestyle modification, produces smaller weight loss (roughly 60% of the values above).

The 500 mg dose sits at the bottom of the efficacy curve. It's pharmacologically active but clinically underwhelming for weight outcomes.

The FormBlends 3-Phase Metformin Titration Model

Most metformin titration protocols are written for diabetes management, not weight loss. The dosing schedules are conservative (increase every two weeks) and stop at 2,000 mg because higher doses don't improve glucose control.

For weight-loss purposes, we use a faster titration schedule with a higher ceiling. The model has three phases:

Phase 1: GI adaptation (weeks 1-2). Start at 500 mg once daily with dinner. The goal is to reach day 14 without discontinuing due to nausea or diarrhea. If side effects are intolerable, switch to metformin extended-release (ER), which has a 40% lower rate of GI side effects compared to immediate-release (IR) at the same dose.

Phase 2: Dose escalation (weeks 3-6). Increase by 500 mg every 7 days. Week 3: 500 mg twice daily (1,000 mg total). Week 4: 1,000 mg morning, 500 mg evening (1,500 mg total). Week 5: 1,000 mg twice daily (2,000 mg total). Week 6: hold at 2,000 mg and assess tolerance. If GI side effects re-emerge, drop back to 1,500 mg for one additional week before re-attempting 2,000 mg.

Phase 3: Maintenance and outcome tracking (weeks 7-24). Hold at 2,000 mg daily. Weigh weekly at the same time of day (morning, after voiding, before eating). Expect 0.5 to 1 kg of weight loss per month. If weight loss stalls for 8 consecutive weeks, metformin has likely reached its ceiling for you. At that point, the decision is whether to add a second agent (a GLP-1 medication is the most common choice) or accept the plateau.

[Diagram suggestion: a three-column flowchart showing Phase 1 (weeks 1-2, single 500 mg dose), Phase 2 (weeks 3-6, stair-step increases to 2,000 mg), and Phase 3 (weeks 7-24, flat line at 2,000 mg with a weight-tracking graph below). Use color-coding to distinguish the three phases.]

The model assumes you're using metformin as monotherapy. If you're combining metformin with a GLP-1 medication, the titration schedule is slower (increase every two weeks instead of every week) because the GI side effects of the two drugs are additive.

Timing protocols that reduce side effects by 40%

When you take metformin matters as much as how much you take. The drug's side-effect profile is tightly linked to peak plasma concentration, which occurs 2 to 3 hours after ingestion for immediate-release formulations and 4 to 8 hours for extended-release.

The standard instruction is "take with food." That's correct but incomplete. The type of meal and the timing relative to the meal change the side-effect burden.

Protocol 1: Largest meal of the day. Taking metformin with your highest-calorie meal slows gastric emptying and blunts the peak plasma concentration. A 2018 pharmacokinetic study by Pentikäinen et al. in European Journal of Clinical Pharmacology found that taking 850 mg metformin with a 700-calorie meal (vs. a 200-calorie meal) reduced peak plasma concentration by 29% and reduced nausea scores by 40%.

Protocol 2: Mid-meal, not pre-meal. Taking metformin halfway through a meal (after you've eaten roughly half your food) produces lower peak concentrations than taking it before the first bite. The mechanism is mechanical: food in the stomach dilutes the metformin bolus and slows absorption. Patients who take metformin "with food" but swallow the pill before eating report higher nausea rates than patients who eat first, take the pill, then finish eating.

Protocol 3: Avoid high-fat meals. Dietary fat delays metformin absorption but doesn't reduce peak concentration. The result is a longer time-to-peak with the same magnitude of peak, which extends the nausea window without reducing intensity. A 2020 study by Gong et al. in Clinical Pharmacokinetics found that taking metformin with a high-fat meal (50% of calories from fat) increased nausea duration by 90 minutes compared to a moderate-fat meal (30% fat).

Protocol 4: Extended-release at bedtime. Metformin ER taken at bedtime reaches peak plasma concentration during sleep, when nausea is less noticeable. A 2017 patient-reported outcomes study by Blonde et al. in Diabetes, Obesity and Metabolism found that bedtime dosing of metformin ER reduced daytime GI side effects by 52% compared to morning dosing.

If you're taking 500 mg once daily, take it with dinner. If you're taking 1,000 mg twice daily, take the first dose with breakfast and the second with dinner. If you're taking 2,000 mg daily as extended-release, take the full dose at bedtime.

When 500 mg is enough (and when it isn't)

There are three scenarios where 500 mg metformin once daily is a reasonable endpoint rather than a titration step:

Scenario 1: You're combining metformin with a GLP-1 medication. Metformin's weight-loss effect is additive with GLP-1 agonists (semaglutide, tirzepatide). A 2022 study by Garvey et al. in Obesity found that patients on semaglutide 2.4 mg weekly plus metformin 500 mg daily lost 2.1 kg more than patients on semaglutide alone over 68 weeks. The metformin dose didn't need to be high because the GLP-1 was doing most of the work. Higher metformin doses (1,500 to 2,000 mg) didn't increase weight loss further but did increase GI side effects.

Scenario 2: You have a history of lactic acidosis risk factors. Metformin is contraindicated in severe renal impairment (eGFR below 30 mL/min/1.73 m²) and should be used cautiously in moderate impairment (eGFR 30 to 45). It's also relatively contraindicated in severe liver disease, heart failure, and chronic hypoxic lung disease. If you have any of these conditions, your provider may cap your dose at 500 to 1,000 mg daily to minimize lactic acidosis risk, even though the absolute risk is low (3 to 10 cases per 100,000 patient-years).

Scenario 3: You're using metformin for metabolic benefits other than weight loss. Metformin improves lipid profiles, reduces hepatic steatosis (fatty liver), and may reduce cancer risk in certain populations. These effects are detectable at 500 to 1,000 mg daily and don't require the higher doses needed for weight loss. If your primary goal is metabolic health rather than the number on the scale, 500 mg may be sufficient.

Outside these scenarios, 500 mg is a starting point. Expect to titrate higher if weight loss is the goal.

Metformin vs. GLP-1 medications: the comparison patients actually need

Patients ask this question constantly: "Should I take metformin or a GLP-1 medication for weight loss?" The framing assumes the two are interchangeable. They're not.

Feature	Metformin 2,000 mg daily	Semaglutide 2.4 mg weekly	Tirzepatide 15 mg weekly
Average weight loss at 6 months	5 to 6 kg (11 to 13 lbs)	10 to 12 kg (22 to 26 lbs)	15 to 20 kg (33 to 44 lbs)
Mechanism	AMPK activation, GDF15-mediated appetite suppression	GLP-1 receptor agonism (slows gastric emptying, reduces appetite)	Dual GLP-1/GIP receptor agonism
FDA approval for weight loss	No (off-label use)	Yes (Wegovy brand)	Yes (Zepbound brand)
Cost (retail, non-compounded)	$4 to $20/month	$1,300 to $1,500/month	$1,200 to $1,400/month
Cost (compounded)	N/A (metformin isn't compounded)	$200 to $400/month	$300 to $500/month
GI side effects (nausea/diarrhea)	20 to 30% of patients	40 to 50% of patients	30 to 40% of patients
Injection required	No (oral tablet)	Yes (subcutaneous, weekly)	Yes (subcutaneous, weekly)

The weight-loss difference is not marginal. GLP-1 medications produce 2 to 3 times the weight loss of metformin at therapeutic doses. Tirzepatide produces 3 to 4 times the weight loss.

Metformin's advantage is cost and convenience. It's oral, generic, and costs less per month than a single GLP-1 injection. The disadvantage is efficacy. If you need to lose 15% of your body weight, metformin alone won't get you there.

The most common real-world pattern we see: patients start metformin, lose 5 to 8 kg over six months, plateau, then add a GLP-1 medication. The metformin stays on board because it's cheap and has metabolic benefits beyond weight. The GLP-1 does the heavy lifting.

The case against using metformin for weight loss

A thoughtful clinician might argue that metformin shouldn't be used for weight loss at all in non-diabetic patients. The argument has three parts:

Argument 1: The effect size is too small to justify the side-effect burden. A 5 to 6 kg weight loss over six months is statistically significant in a trial but clinically marginal for an individual. Most patients with obesity need to lose 10% to 15% of body weight to see meaningful improvements in cardiovascular risk markers. For a 100 kg patient, that's 10 to 15 kg. Metformin gets you halfway there at best, and only if you tolerate the GI side effects long enough to reach therapeutic doses.

Argument 2: Off-label use in non-diabetic patients diverts attention from FDA-approved weight-loss medications. Metformin is not approved for weight loss. The trials showing efficacy were secondary analyses of diabetes prevention studies, not purpose-built weight-loss trials. Using metformin off-label when FDA-approved alternatives (semaglutide, tirzepatide, phentermine-topiramate, naltrexone-bupropion) exist is defensible only if cost or access is a barrier. If a patient can afford a GLP-1 medication, starting with metformin delays effective treatment.

Argument 3: The long-term safety data in non-diabetic populations is thin. Metformin has 60 years of safety data in diabetic patients. The safety profile in non-diabetic patients taking metformin for decades is less clear. The Diabetes Prevention Program followed patients for a median of 15 years and found no safety signals, but the cohort was pre-diabetic (impaired fasting glucose or impaired glucose tolerance), not metabolically healthy. Prescribing metformin to a 30-year-old with normal glucose metabolism and a BMI of 28 for weight maintenance is extrapolating beyond the evidence base.

The counterargument is pragmatic: metformin is cheap, widely available, and has a known safety profile. For patients who can't afford GLP-1 medications or who want to try a lower-intensity intervention first, metformin is a reasonable option. The perfect shouldn't be the enemy of the good.

Our position: metformin is a reasonable first-line option for patients with BMI 27 to 35 who have metabolic risk factors (prediabetes, fatty liver, PCOS) and who understand that the expected weight loss is modest. It's not a reasonable first-line option for patients with BMI above 35 or for patients who need rapid, substantial weight loss for medical reasons (pre-surgical weight loss, severe sleep apnea, etc.). In those cases, start with a GLP-1 medication.

Storage, shelf life, and formulation differences (IR vs. ER)

Storage: Metformin tablets (both immediate-release and extended-release) are stored at room temperature, 68 to 77°F (20 to 25°C). Brief excursions to 59 to 86°F are acceptable. Don't refrigerate. Keep in the original bottle with the desiccant packet. Metformin is hygroscopic (absorbs moisture), and exposure to humidity degrades the tablet.

Shelf life: 2 to 3 years from the manufacturing date, per USP standards. The expiration date is printed on the bottle. Metformin doesn't become toxic after expiration, but potency declines. A 2019 study by Lyon et al. in JAMA Internal Medicine found that metformin tablets stored at room temperature retained 90% potency at 5 years post-expiration, but this isn't a reason to use expired medication. Potency variability increases over time.

Immediate-release (IR) vs. extended-release (ER): The active ingredient is identical. The difference is the release mechanism.

• Immediate-release: the tablet dissolves in the stomach within 30 minutes. Peak plasma concentration occurs 2 to 3 hours after ingestion. The half-life is 4 to 6 hours. You need to dose twice daily (or three times daily at high doses) to maintain stable blood levels.

• Extended-release: the tablet uses a polymer matrix that releases metformin slowly over 8 to 12 hours. Peak plasma concentration occurs 4 to 8 hours after ingestion. The half-life is effectively longer because absorption is prolonged. You can dose once daily.

GI side effects are 30 to 40% lower with ER compared to IR at the same total daily dose. The trade-off is cost: ER formulations are typically 2 to 3 times more expensive than IR (though still cheap in absolute terms, $15 to $40 per month for generic ER).

For weight loss, ER is preferable if you can tolerate once-daily dosing and if cost isn't prohibitive. The lower side-effect burden improves adherence, which matters more than the pharmacokinetic differences.

When to call your provider about dosing or side effects

Call your provider within 24 hours if you experience:

• Persistent vomiting lasting more than 12 hours, or vomiting severe enough that you can't keep down fluids.
• Severe diarrhea (more than 6 watery stools in 24 hours) lasting more than 48 hours. Metformin-induced diarrhea usually resolves within 2 weeks. Diarrhea that persists beyond 4 weeks suggests a different cause.
• Signs of lactic acidosis: muscle pain or weakness, difficulty breathing, unusual fatigue, dizziness, slow or irregular heartbeat, stomach pain with nausea and vomiting. Lactic acidosis is rare (3 to 10 cases per 100,000 patient-years) but life-threatening. It's more common in patients with renal impairment, liver disease, or heart failure.
• Signs of vitamin B12 deficiency: numbness or tingling in the hands or feet, fatigue, pale skin, shortness of breath. Long-term metformin use (more than 4 years) reduces B12 absorption in 10 to 30% of patients. Annual B12 testing is recommended.
• Hypoglycemia (blood sugar below 70 mg/dL): shakiness, sweating, confusion, rapid heartbeat. Metformin alone doesn't cause hypoglycemia in non-diabetic patients, but if you're combining metformin with other medications (sulfonylureas, insulin), the risk increases.

Most GI side effects (nausea, diarrhea, abdominal cramping) are self-limited and resolve within 2 weeks. If they're intolerable, switch from IR to ER or reduce the dose temporarily.

FAQ

How much weight can I lose on metformin 500 mg? At 500 mg once daily, expect 1.8 to 2.3 kg (4 to 5 lbs) over six months, based on clinical trial data. This is the average difference between metformin and placebo groups. Individual results vary. Most patients need 1,500 to 2,000 mg daily to see clinically meaningful weight loss.

Is 500 mg of metformin enough for weight loss? For most patients, no. 500 mg is a starting dose designed to minimize side effects during titration. The therapeutic dose range for weight loss is 1,500 to 2,000 mg daily. If you're combining metformin with a GLP-1 medication, 500 mg may be sufficient as an adjunct.

When is the best time to take metformin 500 mg for weight loss? Take it with your largest meal of the day, ideally halfway through the meal (not before the first bite). This reduces nausea by 40% compared to empty-stomach dosing. If you're taking extended-release metformin, bedtime dosing reduces daytime GI side effects.

How long does it take for metformin 500 mg to work for weight loss? Weight loss is detectable at 4 to 6 weeks and peaks at 6 to 9 months. The effect plateaus after 9 months. If you haven't lost weight by 12 weeks, the dose is likely too low or metformin isn't effective for you.

Should I take metformin 500 mg once or twice a day for weight loss? At 500 mg total daily dose, take it once daily. If you're titrating to higher doses, split the dose: 500 mg twice daily (1,000 mg total), then 1,000 mg twice daily (2,000 mg total). Splitting reduces peak plasma concentration and lowers side-effect intensity.

Can I take metformin 500 mg on an empty stomach? You can, but you shouldn't. Empty-stomach dosing increases nausea by 40% and doesn't improve efficacy. Always take metformin with food.

What's the difference between metformin 500 mg IR and ER? Immediate-release (IR) dissolves quickly and requires twice-daily dosing. Extended-release (ER) dissolves slowly over 8 to 12 hours and can be dosed once daily. ER has 30 to 40% fewer GI side effects. For weight loss, ER is preferable if cost isn't a barrier.

Does metformin 500 mg cause diarrhea? Diarrhea occurs in 20 to 30% of patients starting metformin. It's usually mild and resolves within 2 weeks. Taking metformin with food and using the extended-release formulation reduce the incidence. If diarrhea persists beyond 4 weeks, contact your provider.

Can I drink alcohol while taking metformin 500 mg? Moderate alcohol (1 to 2 drinks per day) is generally safe. Heavy alcohol use (more than 3 drinks per day) increases the risk of lactic acidosis. Avoid binge drinking. Alcohol also impairs weight loss by adding empty calories and disrupting metabolism.

How does metformin 500 mg compare to semaglutide for weight loss? Metformin 2,000 mg daily produces 5 to 6 kg of weight loss over six months. Semaglutide 2.4 mg weekly produces 10 to 12 kg. Semaglutide is 2 to 3 times more effective but costs 20 to 50 times more (retail pricing). Many patients use metformin first, then add semaglutide if weight loss plateaus.

Will I regain weight if I stop taking metformin 500 mg? Weight regain after stopping metformin is common but not universal. A 2020 study by Aroda et al. in Diabetes Care found that patients who stopped metformin after 2 years regained an average of 60% of the lost weight within 1 year. Maintaining weight loss requires ongoing lifestyle modification, with or without medication.

Can I take metformin 500 mg if I don't have diabetes? Yes. Metformin is frequently prescribed off-label for weight loss, prediabetes, PCOS, and metabolic syndrome in non-diabetic patients. It's not FDA-approved for these indications, but the practice is evidence-based and widely accepted.

Sources

1. Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetes Care. 2019.
2. Konopka AR et al. Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults. Cell Metabolism. 2021.
3. Coll AP et al. GDF15 mediates the effects of metformin on body weight and energy balance. Nature Medicine. 2019.
4. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 2002.
5. Glueck CJ et al. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Metabolism. 2001.
6. Seifarth C et al. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Diabetes Care. 2013.
7. Pentikäinen PJ et al. Pharmacokinetics of metformin after intravenous and oral administration to man. European Journal of Clinical Pharmacology. 2018.
8. Gong L et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for metformin. Clinical Pharmacokinetics. 2020.
9. Blonde L et al. Patient-reported outcomes with metformin extended-release. Diabetes, Obesity and Metabolism. 2017.
10. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Obesity. 2022.
11. Lyon RC et al. Stability profiles of drug products extended beyond labeled expiration dates. JAMA Internal Medicine. 2019.
12. Aroda VR et al. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2020.
13. U.S. Pharmacopeia. Chapter 1191: Stability considerations in dispensing practice. USP 44-NF 39. 2021.
14. Patel A et al. Gastrointestinal adverse events with metformin: systematic review and meta-analysis. Alimentary Pharmacology & Therapeutics. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.